Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease

The prevalence of coronary artery disease (CAD) increases in patients with end-stage liver disease, with part of them receiving the percutaneous coronary intervention (PCI) as a treatment option. Dual antiplatelet therapy (DAPT), a standard of care after PCI, could result in catastrophic consequence...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostojic, Zvonimir, Ostojic, Ana, Bulum, Josko, Mrzljak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Opinion Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641002/
https://www.ncbi.nlm.nih.gov/pubmed/34909126
http://dx.doi.org/10.4330/wjc.v13.i11.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641002/
https://www.ncbi.nlm.nih.gov/pubmed/34909126
http://dx.doi.org/10.4330/wjc.v13.i11.599

Ejemplares similares